Development and validation of measures for assessing ultra-high risk criteria for emerging personality disorders
Recruiting
- Conditions
- Personality disorders10034726
- Registration Number
- NL-OMON56497
- Lead Sponsor
- niversiteit van Tilburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 114
Inclusion Criteria
The clinical sample consists of children and adolescents (and their parents)
enrolled in MST-CAN, a treatment programme for families where there is
objectified maltreatment. The control sample is a community sample.
Participants are both children/adolescents and their parent(s). Children must
be between 10 and 15 years old.
Exclusion Criteria
Inability to participate in interviews or questionnaires due to insufficient
command of language, intelligence or for other reasons
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>De primaire uitkomstmaten zijn de scores op elk van de instrumenten voor<br /><br>UHR-criteria. We verwachten op alle criteria hogere gemiddeldes in de<br /><br>risicosteekproef dan in de samenlevingssteekproef.<br /><br><br /><br>The primary outcome is the score on each of the instruments meant to assess the<br /><br>UHR-criteria. We predict higher mean scores in the risk sample then in the<br /><br>cohort sample for all criteria.</p><br>
- Secondary Outcome Measures
Name Time Method <p>not applicable</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the ultra-high risk criteria for emerging personality disorders in the NL-OMON56497 trial?
How do the UHR criteria for personality disorders in NL-OMON56497 compare to standard diagnostic frameworks like DSM-5 and ICD-11?
Are there specific biomarkers identified in the NL-OMON56497 trial that correlate with early detection of personality disorder subtypes?
What are the potential adverse events associated with early intervention strategies for ultra-high risk personality disorder criteria?
How does the observational design of NL-OMON56497 contribute to understanding longitudinal outcomes in personality disorder risk assessment?